CorNav and Mayo Clinic Team Up for Innovative Heart Treatments
CorNav Corporation Partners with Mayo Clinic
CorNav Corporation, based in Boulder, is pioneering advancements in cardiac care through its collaboration with the esteemed Mayo Clinic. This partnership aims to enhance treatments for patients facing ventricular tachycardia (VT), especially those who find little relief from traditional medications. The focus is on creating targeted therapies that can effectively reach the epicardial surface of the heart.
A New Approach to Ventricular Tachycardia
The collaboration features a significant milestone: a know-how agreement specifically directed at developing the innovative CardioScout™ Epicardial Access System. This device represents a revolutionary approach to treating VT that originates on the outer layer of the heart, seeking to improve outcomes for countless individuals with this serious condition.
Background of the Collaboration
This agreement follows an initial partnership previously initiated to develop solutions for congestive heart failure. The new project is led by James Fonger, M.D., founder and CEO of CorNav, who emphasizes the urgency and necessity of addressing VT, a condition affecting millions both domestically and globally.
Understanding Ventricular Tachycardia
Ventricular tachycardia is an alarming heart rhythm disorder, contributing to over 350,000 sudden cardiac deaths each year. Despite existing procedures, current methods of epicardial VT ablation often rely on off-label techniques using catheters that are primarily intended for endocardial use. This misalignment can result in poor visualization of key cardiac structures, leading to procedural difficulties and substandard patient outcomes.
Innovative Technology: CardioScout Epicardial Access System
Introducing the CardioScout minimally invasive endoscopic platform, which allows for agile navigation across the epicardial surface of the heart to perform VT ablation. The access is achieved through a small incision, enhancing patient comfort and procedural efficacy. The embedded scope is designed to provide real-time, high-definition imaging, ensuring precise navigation and treatment application.
Key Features of the CardioScout System
The system’s flexible catheter body mimics the natural form of the human spine, allowing it to conform comfortably to the heart's contours. Once positioned, the device utilizes LED lighting and high-resolution imaging, dramatically increasing the safety and efficiency of VT ablation procedures.
The Future of VT Ablation
In discussing the partnership, Dr. Fonger noted, "The opportunity to collaborate with the Mayo Clinic is extraordinary. This collaboration will significantly enhance our advancements, making EP ablation procedures faster, safer, and more effective, ultimately leading to improved patient outcomes. We are optimistic about the potential of this partnership."
Mayo Clinic’s Role in the Collaboration
The Mayo Clinic, with its vast experience and reputation in patient care and research, will be a critical player in this initiative. Any revenue generated from this collaboration will support their mission to drive healthcare innovation and patient-centric education.
About CorNav Corporation
CorNav Corporation stands at the forefront of developing advanced cardiac solutions, having been established by Dr. James Fonger, a leading figure in minimally invasive cardiothoracic surgery. With his expertise, CorNav is set to influence the future of cardiac treatment through innovative technologies.
Frequently Asked Questions
What is the purpose of the collaboration between CorNav and Mayo Clinic?
The collaboration aims to develop a new technology for treating ventricular tachycardia, focusing on minimally invasive targeted therapies.
What is the CardioScout Epicardial Access System?
The CardioScout is a minimally invasive platform designed to navigate the epicardial surface of the heart, facilitating more effective VT ablation procedures.
Why is ventricular tachycardia a concern?
Ventricular tachycardia is a dangerous cardiac rhythm disorder that significantly contributes to sudden cardiac deaths, making effective treatment vital.
How does the new technology improve patient outcomes?
The technology provides better visualization and navigation during procedures, making them safer and more efficient, leading to improved patient care.
Who founded CorNav Corporation?
CorNav Corporation was founded by Dr. James Fonger, a specialist with extensive experience in minimally invasive cardiothoracic surgery.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
